GeneDx Holdings (WGS) Free Cash Flow (2020 - 2026)

GeneDx Holdings (WGS) has reported Free Cash Flow for 7 consecutive years, with -$39.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Free Cash Flow fell 585.59% year-over-year to -$39.1 million in Q2 2026; TTM through Jun 2026 was -$75.8 million, a 9232.29% decrease from a year earlier, with the FY2025 full-year figure at $14.3 million, up 141.96% from the prior year.
• Free Cash Flow was -$39.1 million for Q2 2026 at GeneDx Holdings, down from -$38.9 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $9.6 million in Q3 2025 and troughed at -$90.4 million in Q3 2022.
• A 5-year average of -$33.9 million and a median of -$35.5 million in 2023 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow jumped 284.09% in 2025 and slumped 1058.82% in 2026, its largest moves.
• Over 5 years, Free Cash Flow stood at -$65.3 million in 2022, then jumped by 50.66% to -$32.2 million in 2023, then jumped by 81.19% to -$6.1 million in 2024, then fell by 22.68% to -$7.4 million in 2025, then plunged by 425.68% to -$39.1 million in 2026.
• The last three Free Cash Flow figures came in at -$39.1 million (Q2 2026), -$38.9 million (Q1 2026), and -$7.4 million (Q4 2025), per Business Quant data.